Dominion Diagnostics -- The Only Specialty Urine Drug Monitoring Laboratory to Offer Quantitative Detection of Tapentadol (Nucynta(TM)) b... ( NORTH KINGSTOWN R.I. Sept. 14 /...)

HOME >> MEDICINE >> NEWS

Dominion Diagnostics -- The Only Specialty Urine Drug Monitoring Laboratory to Offer Quantitative Detection of Tapentadol (Nucynta(TM)) by LC/MS/MS

Date:9/14/2009

NORTH KINGSTOWN, R.I., Sept. 14 /PRNewswire/ -- Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

Dominion's new assay by LC/MS/MS can detect and identify the primary drug tapentadol. Tapentadol is extensively metabolized in humans. In clinical studies 97% of the administered dose was metabolized, with 70% of the dose excreted in the urine in the conjugated form (55% as tapentadol-O-glucuronide and 15% and tapentadol-O-sulfate). Tapentadol excretion is almost exclusively renal. In a clinical study, it was shown that greater than 95% of a single dose of tapentadol was excreted in the urine within 24 hours of oral administration(1).

"This is a noteworthy achievement for our Research & Development (R&D) and Laboratory Teams," stated Chief Operating Officer Stephen Jordan. "Dominion has invested considerable time and resources in developing this new tapentadol assay. Providing assays for new pain medications allows us to better support our clients' need for relevant and accurate technologies when relying on urine drug monitoring to support patient adherence."

Dominion's quantitative tapentadol assay, one of the first presented to the industry, is now available to all clients across the country. This new development comes as part of Dominion's continued commitment to unparalleled laboratory excellence. Dominion continues to lead the industry in its quest for accurate, clinically relevant science for use in appropriately monitoring chronic pain patients. Dominion's R&D team actively works wit
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine news :

1. Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility
2. Dominion Helps Communities by Donating $1 Million to Health Clinics
3. Capital BlueCross Acquires Dominion Dental
4. Dominion Diagnostics Announces Launch of Comprehensive New Company Website
5. Dominion Diagnostics Supports Rhode Islands Toys for Tots Initiative at Its 2007 Holiday Celebration
6. Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
7. Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index
8. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
9. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
10. Quest Diagnostics Declares Quarterly Cash Dividend
11. eCardio Diagnostics Expands Corporate Management Team

Post Your Comments:

Dominion Diagnostics -- The Only Specialty Urine Drug Monitoring Laboratory to Offer Quantitative Detection of Tapentadol (Nucynta(TM)) b...( NORTH KINGSTOWN R.I. Sept. 14 /...),Health